MAPK10-AS1

Across TCGA pan-cancer cohorts, MAPK10-AS1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MAPK10-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MAPK10-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types MAPK10-AS1 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and ESCA are the cancer types where MAPK10-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAPK10-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	III,IV	−0.177	.004	6	view →
THCA	All	All	−0.071	.006	3	view →
ESCA	Female	All	−0.100	.019	1	view →
LUSC	Male	All	+0.049	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MAPK10-AS1–BLCA

Open the BLCA breakdown →